Strongin Z, et al. Distinct SIV-specific CD8+ T in lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence. Nat Immunol. 2024 June 17

Harper J, et al. Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner? Pathog Immun. 2024 Mar 12;8(2):179-222. doi: 10.20411/pai.v8i2.696. eCollection 2023. PMID: 38505662.

Benlarbi M, et al. Plasmatic HIV-1 soluble gp120 is associated with correlates of immune dysfunction and inflammation in ART-treated individuals with undetectable viremia. Journal Infect. Dis. 2024 Mar 14;229(3):763-774. doi: 10.1093/infdis/jiad503.

Armani-Tourret M, et al. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a. Cell, 2024 Feb 16:S0092-8674(24)00105-3. doi: 10.1016/j.cell.2024.01.037. PMID: 38367616.

Passaes C, et al. Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells. Nat Commun. 2024 024 Jan 11;15(1):178. doi: 10.1038/s41467-023-44389-3. PMID: 38212337

Docken SS, et al. Preferential selection of viral escape mutants by CD8+ T cell ‘sieving’ of SIV reactivation from latency. Plos Pathogens 2023. Nov 30;19(11):e1011755. doi: 10.1371/journal.ppat.1011755. eCollection 2023 Nov. PMID: 3803285.

Anang S, et al. V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins. J Virol. 2023 Nov 30;97(11):e0117123. doi: 10.1128/jvi.01171-23. Epub 2023 Oct 27. PMID: 37888980; PMCID: PMC10688366.

Pinkevych M, et al. Timing of initiation of anti-retroviral therapy predicts post-treatment control of SIV replication. PLoS Pathog. 2023 Oct 6;19(10):e1011660. doi: 10.1371/journal.ppat.1011660. eCollection 2023 Oct. PMID: 37801446.

Zhang Z, et al. Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation. J Virol. 2023 Sep 28;97(9):e0059223. doi: 10.1128/jvi.00592-23. Epub 2023 Sep 11. PMID: 37696048.

Marchitto L, et al. Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity. mBio. 2023 Aug 31;14(4):e0078923. doi: 10.1128/mbio.00789-23. Epub 2023 Jul 5. PMID: 37404017.

Kuzmichev YV, et al. Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assays. Sci Rep. 2023 Jul 6;13(1):10958. doi: 10.1038/s41598-023-37223-9. PMID: 37414788.

Zhou R, et al. Conformations of human immunodeficiency virus (HIV-1) envelope glycoproteins in detergents and styrene-maleic acid lipid particles. J Virol. 2023 Jun 29;97(6):e0032723. doi: 10.1128/jvi.00327-23. Epub 2023 May 31. PMID: 37255444; PMCID: PMC10308955.

Samer S, et al. Lymph-node based CD3+CD20+ cells emerge from membrane exchange between T follicular helper cells and B cells and increase their frequency following Simian Immunodeficiency Virus infection. J Virol. 2023 Jun 29;97(6):e0176022. doi: 10.1128/jvi.01760-22. Epub 2023 May 23. PMID: 37223960.

Chatterjee D, et al. Identification of aryl hydrocarbon receptor as a barrier to HIV-1 infection and outgrowth in CD4+ T cells. Cell Rep. 2023 Jun 12;42(6):112634. doi:10.1016/j.celrep.2023.112634.

Ding S, et al A. Piperidine CD4-Minetic compounds expose vulnerable Env epitopes sensitizing HIV-1-infected cells to ADCC. Viruses. 2023 May 17;15(5):1185. doi: 10.3390/v15051185. PMID: 37243271.

Boutin M, et al. Temsavir modulate HIV-1 envelope conformation by decreasing its proteolytic cleavage. Viruses. 2023 May 18;15(5):1189. doi: 10.3390/v15051189. PMID: 37243275.

Mutascio S, et al. CD8+ T cells promote HIV latency through induction of CD4+ T cell survival, quiescence, and stemness. Immunity. 2023 May 9;56(5):1132-1147.e6. doi: 10.1016/j.immuni.2023.03.010. Epub 2023 Apr 7. PMID: 37030290.

Mallarino-Haeger C, et al. HIV-1 DNA and Immune Activation Levels Differ for Long-Lived T-Cells in Lymph Nodes, Compared with Peripheral Blood, during Antiretroviral Therapy. J Virol. 2023 Mar 27:e0167022. doi: 10.1128/jvi.01670-22. PMID: 36971588.

Fritschi CJ, et al. Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity. Proc Natl Acad Sci U S A. 2023 Mar 28;120(13):e2222073120. doi: 10.1073/pnas.2222073120. Epub 2023 Mar 24. PMID: 36961924.

Statzu M, et al. The latent SIV reservoir under ART is established independent of CD8+ lymphocyte control. Nature Microbiology 2023. Nat Microbiol. 2023 Jan 23. doi: 10.1038/s41564-022-01311-9 PMID: 36690860.

Sun W, et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature. 2023. doi: 10.1038/s41586-022-05538-8. Epub 2023 Jan 4. PMID: 36599977

Chaplain C, et al. Structural and functional characterization of indane-core CD4-mimetic compounds substituted with heterocyclic amines. ACS Med Chem Lett. 2022 Dec 6;14(1):51-58. doi: 10.1021/acsmedchemlett.2c00376. PMID: 36655122

Chandrasekar AP, et al. The BCL-2 inhibitor Venetoclax augments immune effector function mediated by Fas lognad TRAIL, and Perforin/Granzyme B, resulating in reduced plasma viremia and decreased HIV reservoir size during acute HIV infection in a humanized mouse model. J Virol. 2022 Dec 21;96(24):e0173022. doi: 10.1128/jvi.01730-22. Epub 2022 Nov 30. PMID: 36448802.

Prevost J, et al. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Cell Rep. 2022 Nov 8;41(6):111624. doi: 10.1016/j.celrep.2022.111624. PMID: 36351384.

Anang S, et al. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound. J Virol. 2022 Sep 14;96(17):e0063622. doi: 10.1128/jvi.00636-22. Epub 2022 Aug 18. PMID: 35980207.

Strongin Z, et al. The role of Cd101-expressing CD4 T cells in HIV/SIV pathogenesis and persistence. PLoS Pathog. 2022 Jul 22;18(7):e1010723. doi: 10.1371/journal.ppat.1010723. eCollection 2022 Jul. PMID: 35867722.

Boutin M, et al. Temsavir treatment of HIV-1-infected cells decreases envelope glycoprotein recognition by broadly neutralizing antibodies. mBio 2022 Jun28;13(3):e0057722.dol:10.128/mBio.00577-22. PMID: 3547564.

Perdomo-Celis F, et al. Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. J Clin Invest. 2022 Jun 1;132(11):e157549. doi: 10.1172/JCI157549. PMID: 35380989.

Verdikt R, et al. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine. 2022 May;79:103985. doi: 10.1016/j.ebiom.2022.103985. Epub 2022 Apr 14. PMID: 35429693.

Robinson CA, et al. Novel Compound Inhibitors of HIV-1 NL4-3 Vpu. Viruses. 15 April 2022. PMID: 35458546.

Leyre L, et al. Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity. JCI 2022. Apr1;132(7):1-4. Doi:101172/ICI157549. PMID:35362485.

Harper J, et al. Interleukin-10 contributes to reservoir establishment and persistence in antiretroviral therapy-treated, SIV-infected macaques. JCI, 2022. Apr 15;132(8):e155251. doi: 10.1172/JCI155251.PMID: 35230978.

Prévost J, et al. Detection of the HIV-1 accessory proteins Nef and Vpu by flow cytometry represents a new tool to study their functional interplay within a single infected CD4+ T cell. J Virol. 2022 Mar 23;96(6):e0192921. doi: 10.1128/jvi.01929-21. Epub 2022 Jan 26. PMID: 35080425.

Einkauf KB, et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell, 2022, Jan 20; doi: 10.1016/j.cell.2021.12.011. Epub 2022 Jan 12. PMID:35026153.

Prévost J, et al. HIV-1 envelope glycoproteins proteolytic cleavage protects infected cells from ADCC mediated by plasma from infected individuals. Viruses, 2021. 13(11), 2236

Cummins NW et al.“Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.” E clinical medicine